Citations

Mayo Clinic

Showing 10 of 108599 citations.

Diffuse Cerebral Edema With Uncal Herniation Leading to Brain Death in Patient With Fulminant Susac syndrome: Rare Complication of Rare Disease
Tsikvadze, Mariam , Villafane, Baltazar Machado De , Rose, Mariah Q., Peacock, Sarah , Peel, Jeffrey B. , Ng, Lauren , Kramer, Christopher, Freeman, William D. , Machado De Villafane, Baltazar , Rose, Mariah, Peel, Jeffrey Brent, Freeman, William D , Kramer, Christopher

The Neurohospitalist | August 23, 2023 | Volume: 14 | Issue: 1 | Pages: 87-94

10.1177/19418744231196625 | PMID 38235024 Get It

Susac Syndrome was first described as an inflammatory microangiopathy of the brain and retina. Since then, multiple articles have been published in attempts to improve the understanding of this rare disease. Clinically Susac Syndrome is known to present with triad of encephalopathy, sensorineural hearing loss and branch of retinal artery occlusion (BRAO), along with characteristic “snowball” or “spoke” appearing white matter lesions of the corpus callosum. It has been characterized by vast heterogeneity in terms of its presenting symptoms, severity, and clinical course. Although subset of patients present with severe forms of Susac Syndrome and can develop prominent residual neurologic deficits, it has been reported to be mostly non-life-threatening and only few fatal cases have been described in the literature. Based on the available case reports with fatal outcome, mortality has been related to the systemic complications either during acute disease flare or during chronic-progressive phase. We describe a case of fulminant Susac Syndrome complicated by the sudden and rapid progression of diffuse cerebral edema leading to brain herniation and ultimate brain death, in order to increase awareness of this rare and catastrophic complication.
Two Cases of Periodic Paralysis Associated With MCM3AP Variants
Oishi, Tatsuya , Pagano, J.V., Sellers, Cody, Jerath, Nivedita U. , Oishi, Tatsuya , Pagano, Jennifer, Sellers, Cody N

Journal of Clinical Neuromuscular Disease | August 23, 2023 | Volume: 25 | Issue: 1 | Pages: 36-41

10.1097/cnd.0000000000000454 | PMID 37611268 Get It

Abstract Objectives: Periodic paralysis is a rare genetic condition characterized by episodes of neuromuscular weakness, often provoked by electrolyte abnormalities, physiologic stress, physical exertion, and diet. In addition to mutations in genes coding for skeletal muscle ion channels, in 2019, Gustavasson et al discovered that the MCM3AP gene could be responsible for periodic paralysis. In this study, we present 2 individuals with clinical episodes of periodic paralysis who have variants in the MCM3AP gene. Methods: Two unrelated probands were independently evaluated with clinical, genetic, and electrodiagnostic testing. Results: Proband 1 is a 46-year-old man who presented with decades of ongoing episodic weakness and fatigue, clinically diagnosed with periodic paralysis and supported by electrodiagnostic studies. Proband 2 is a 34-year-old woman with a history of episodic paralysis since childhood. Genetic testing in both individuals revealed potentially pathogenic variants in the MCM3AP gene. Conclusions: Periodic paralysis is a condition that significantly affects the lives of those diagnosed. The results illustrate that MCM3AP gene variants can been associated with a clinical and electrodiagnostic presentation of periodic paralysis. Additional future research should focus on clarifying any relationship between these genetic variants and the disease, as well as other possible genetic causes.
Functional and translational consequences of immunometabolic coevolution in ccRCC
Tang, Cerise, Xie, Amy , Golkaram, Mahdi , Gupta, Sounak , Russo, Paul , Carloa, Maria, Tansey, Wesley , Reznik, Ed , Liu, Eric Minwei , Kuo, Fengshen , Kim, Min‐Soo , Chen, Ying‐Bei , Motzer, Robert J. , Coleman, Jonathan , Voss, Martin H. , Kotecha, Ritesh R. , Lee, Chung‐Han , Schultz, Nikolaus D. , Hakimi, A Ari

The Oncologist | August 23, 2023 | Volume: 28 | Issue: Supplement_1 | Pages: S1-S2

10.1093/oncolo/oyad216.003 Get It

Abstract Background Tumor cell phenotypes and anti-tumor immune responses are shaped by local metabolite availability, but intratumoral metabolite heterogeneity (IMH) and its phenotypic consequences remain poorly understood. In vitro mechanistic studies have demonstrated that the anti-tumor activity of lymphoid and myeloid cell populations is mediated by metabolite availability and signaling in the TME, raising the possibility that the immune response and metabolism of ccRCC tumors coevolve and jointly influence the likelihood that a patient responds to therapy.. However, both the broad patterns of coordination between metabolite abundance and TME cellular composition, as well as the precise cell populations producing metabolic phenotypes of interest, remain unknown. Methods To study IMH, we multiregionally profiled the metabolome, transcriptome, and genome of 187 tumor/normal regions from 31 clear cell renal cell carcinoma (ccRCC) patients. Using these measurements and additional multimodal metabolomic/transcriptomic profiling of ccRCC and other diseases, we developed computational models that can be used to understand RNA-metabolite covariation and ultimately impute metabolite levels from RNA sequencing data. Results Analysis of intratumoral metabolite-RNA covariation revealed that the immune composition of the microenvironment, and especially the abundance of myeloid cells, drove intratumoral metabolite variation. Motivated by the strength of RNA-metabolite covariation and the clinical significance of RNA biomarkers in ccRCC, we deployed and benchmarked a machine learning method (MIRTH) to impute metabolite levels directly from RNA sequencing data of primary and metastatic ccRCC tumors. We inferred metabolomic profiles from RNA sequencing data of ccRCC patients enrolled in 6 clinical trials, ultimately identifying specific metabolite biomarkers associated with response to anti-angiogenic agents. Conclusions Local metabolic phenotypes therefore emerge in tandem with the immune microenvironment and associate with therapeutic sensitivity. CDMRP DOD Funding: yes
PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Kumar, Shaji , Leleu, Xavier , Popat, Rakesh , Craigie, Samantha, Patel, Leena , Ramirez, Abril Oliva, Ge, Wenzhen , Ma, Qiufei , Weisel, Katja C , Popat, Rakesh , Patel, Leena, Hampp, Christian , Jagannath, Sundar

HemaSphere | August 23, 2023 | Volume: 7 | Issue: S3 | Pages: e9426734

10.1097/01.hs9.0000975152.94267.34 Get It

PB1888: TRIAL IN PROGRESS: PHASE 1B/2 STUDY OF PIVEKIMAB SUNIRINE (PVEK, IMGN632) IN COMBINATION WITH VENETOCLAX/AZACITIDINE OR MAGROLIMAB FOR PATIENTS WITH CD123-POSITIVE ACUTE MYELOID LEUKEMIA (AML)
Aribi, Ahmed , Altman, Jessica K. , Benga, Kebede, Sloss, Callum M., Malcolm, Kara E, Sweet, Kendra , Daver, Naval , Montesinos, Pau , Martinelli, Giovanni , Wang, Eunice S. , Roboz, Gail J. , Burke, Patrick W. , Walter, Roland B. , Zweidler-McKay, Patrick A

HemaSphere | August 23, 2023 | Volume: 7 | Issue: S3 | Pages: e12654b3

10.1097/01.hs9.0000974376.12654.b3 Get It

The kinesin-5 tail and bipolar minifilament domains are the origin of its microtubule crosslinking and sliding activity
Nithianantham, Stanley , Iwanski, Malina K. , Gaska, Ignas , Bodrug, Tatyana , Inagaki, Sayaka , Major, Jennifer , Brouhard, Gary J. , Gheber, Larissa, Rosenfeld, Steven S. , Forth, Scott , Hendricks, Adam G , Al-Bassam, Jawdat , Pandey, Himanshu , Forth, Scott

Molecular Biology of the Cell | August 23, 2023 | Volume: 34 | Issue: 11 | Pages: No page available

10.1091/mbc.e23-07-0287 | PMID 37610838 Get It

Kinesin-5 crosslinks and slides apart microtubules to assemble, elongate, and maintain the mitotic spindle. Kinesin-5 is a tetramer, where two N-terminal motor domains are positioned at each end of the motor, and the coiled-coil stalk domains are organized into a tetrameric bundle through the bipolar assembly (BASS) domain. To dissect the function of the individual structural elements of the motor, we constructed a minimal kinesin-5 tetramer (mini-tetramer). We determined the x-ray structure of the extended, 34-nm BASS domain. Guided by these structural studies, we generated active bipolar kinesin-5 mini-tetramer motors from Drosophila melanogastor and human orthologues which are half the length of native kinesin-5. We then used these kinesin-5 mini-tetramers to examine the role of two unique structural adaptations of kinesin-5: 1) the length and flexibility of the tetramer, and 2) the C-terminal tails which interact with the motor domains to coordinate their ATPase activity. The C-terminal domain causes frequent pausing and clustering of kinesin-5. By comparing microtubule crosslinking and sliding by mini-tetramer and full-length kinesin-5, we find that both the length and flexibility of kinesin-5 and the C-terminal tails govern its ability to crosslink microtubules. Once crosslinked, stiffer mini-tetramers slide antiparallel microtubules more efficiently than full-length motors.
Recommendations for Deferred Testing in Low-Risk Chest Pain—Decades Old But Now Finally Tested
Gibbons, Raymond J.

JAMA Cardiology | August 23, 2023 | Volume: 8 | Issue: 10 | Pages: 924

10.1001/jamacardio.2023.2715 | PMID 37610740 Get It

Radiomics for differentiation of gliomas from primary central nervous system lymphomas: a systematic review and meta-analysis
Garaba, Alexandru , Aslam, Nummra, Awadhi, Abdullah Al , Panciani, Pier Paolo , Brinjikji, Waleed , Ponzio, Francesco , Fontanella, Marco Maria , Maria, Lucio De

No container title available | August 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3275043/v1 Get It

Abstract Purpose: Numerous radiomics-based models have been proposed to discriminate between central nervous system (CNS) gliomas and primary central nervous system lymphomas (PCNSLs). Given the heterogeneity of the existing models, we aimed to define their overall performance and identify the most critical variables to pilot future algorithms. Methods: A systematic review of the literature and a meta-analysis were conducted, focusing on studies reporting on radiomics to differentiate gliomas from PCNSLs. A comprehensive literature search was performed through PubMed, Ovid MEDLINE, Ovid EMBASE, Web of Science, and Scopus databases. Overall sensitivity (SEN) and specificity (SPE) were estimated. Event rates were pooled using a random-effects meta-analysis, and the heterogeneity was assessed using the χ2 test. Results: The overall SEN and SPE for differentiation between CNS gliomas and PCNSLs were 88% (95% CI = 0.83 – 0.91) and 87% (95% CI = 0.83 – 0.91), respectively. The best-performing features were the Gray Level Run Length Matrix (GLRLM; ACC 97%), followed by the Neighboring Gray Tone Difference Matrix (NGTDM; ACC 93%), and shape-based features (ACC 91%). The 18F-FDG-PET/CT was the best-performing imaging modality (ACC 97%), followed by the MRI CE-T1W (AUC 87% - 95%). Most studies applied a cross-validation analysis (92%). Conclusion: The current SEN and SPE of radiomics to discriminate CNS gliomas from PCNSLs are high, making radiomics a helpful method to differentiate these tumor types. The best-performing features are the GLRLM, NGTDM, and shape-based features. The 18F-FDG-PET/CTimaging modality is the best-performing, while the MRI CE-T1W is the most used.
Experts Achieve Consensus on a Majority of Statements Regarding Platelet‐Rich Plasma Treatments for Treatment of Musculoskeletal Pathology
Hurley, Eoghan T. , Sherman, Seth L. , Stokes, Daniel J. , Shapiro, Shane A. , Mautner, Kenneth , Buford, Don , Dragoo, Jason L. , Mandelbaum, Bert R. , Zaslav, Kenneth R. , Cole, Brian J. , Hall, Mederic M. , Piuzzi, Nicolás S. , Shapiro, Shane , Mautner, Kenneth R , Rodeo, Scott A. , Frank, Rachel M , Kon, Elizaveta

Arthroscopy | August 23, 2023 | Volume: 40 | Issue: 2 | Pages: 470

10.1016/j.arthro.2023.08.020 | PMID 37625660 Get It

Purpose To establish consensus statements on platelet‐rich plasma (PRP) for the treatment of musculoskeletal pathologies. Methods A consensus process on the treatment of PRP using a modified Delphi technique was conducted. Thirty‐five orthopaedic surgeons and sports medicine physicians participated in these consensus statements on PRP. The participants were composed of representatives of the Biologic Association, representing 9 international orthopaedic and musculoskeletal professional societies invited due to their active interest in the study of orthobiologics. Consensus was defined as achieving 80% to 89% agreement, strong consensus was defined as 90% to 99% agreement, and unanimous consensus was indicated by 100% agreement with a proposed statement. Results There was consensus on 62% of statements about PRP. Conclusions (1) PRP should be classified based on platelet count, leukocyte count, red blood count, activation method, and pure‐plasma versus fibrin matrix; (2) PRP characteristics for reporting in research studies are platelet count, leukocyte count, neutrophil count, red blood cell count, total volume, the volume of injection, delivery method, and the number of injections; (3) the prognostic factors for those undergoing PRP injections are age, body mass index, severity/grade of pathology, chronicity of pathology, prior injections and response, primary diagnosis (primary vs postsurgery vs post‐trauma vs psoriatic), comorbidities, and smoking; (4) regarding age and body mass index, there is no minimum or maximum, but clinical judgment should be used at extremes of either; (5) the ideal dose of PRP is undetermined; and (6) the minimal volume required is unclear and may depend on the pathology. Level of Evidence Level V, expert opinion.